Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
5.32
+0.09 (1.72%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Nutriband Revenue
Nutriband had revenue of $645.80K in the quarter ending October 31, 2024, with 50.94% growth. This brings the company's revenue in the last twelve months to $2.02M, down -3.18% year-over-year. In the fiscal year ending January 31, 2024, Nutriband had annual revenue of $2.09M with 0.27% growth.
Revenue (ttm)
$2.02M
Revenue Growth
-3.18%
P/S Ratio
26.08
Revenue / Employee
$155,521
Employees
13
Market Cap
59.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
NTRB News
- 13 days ago - Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology - GlobeNewsWire
- 20 days ago - UPDATE – Nutriband Signs Associate Partnership with Charlotte FC - GlobeNewsWire
- 20 days ago - Nutriband Signs Partnership Agreement with Charlotte FC - GlobeNewsWire
- 2 months ago - Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development. - GlobeNewsWire
- 2 months ago - Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 2 months ago - Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™ - GlobeNewsWire
- 4 months ago - Nutriband Issues Letter to Shareholders - GlobeNewsWire
- 4 months ago - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology - GlobeNewsWire